tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
InnoCare Pharma Ltd. (HK:9969)
HKEX:9969
Hong Kong Market
9969
InnoCare Pharma Ltd.
Stock Analysis
Analyst Forecasts
Technical Analysis
Chart
Earnings
Dividends
Ownership
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding HK:9969?
Track your performance easily
Link Broker

InnoCare Pharma Ltd. (9969) Stock Price & Analysis

0 Followers

9969 Stock Chart & Stats

Advanced Chart >
Day’s RangeHK$0 - HK$0
52-Week RangeHK$4.03 - HK$7.92
Previous CloseHK$6.16
Volume5.19M
Average Volume (3M)6.67M
Market Cap
HK$9.22B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 20, 2025
EPS Estimate
-HK$0.09
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding249,728,111
10 Day Avg. Volume7,462,510
30 Day Avg. Volume6,673,509
Standard Deviation0.17
R-Squared0.24
Alpha0.00403
Financial Highlights & Ratios
Price to Book (P/B)335.50
Price to Sales (P/S)12.59
Price to Cash Flow (P/CF)-29.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.80
Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

InnoCare Pharma Ltd. News

InnoCare Pharma Updates on Funds Utilization Strategy
PremiumCompany Announcements
InnoCare Pharma Updates on Funds Utilization Strategy
12d ago
9969
InnoCare Announces Breakthrough Psoriasis Drug Results
PremiumCompany Announcements
InnoCare Announces Breakthrough Psoriasis Drug Results
2M ago
9969
InnoCare Pharma Reveals Board Structure
PremiumCompany Announcements
InnoCare Pharma Reveals Board Structure
2M ago
9969
InnoCare Pharma Announces Board Reshuffle
PremiumCompany Announcements
InnoCare Pharma Announces Board Reshuffle
2M ago
9969
InnoCare Advances MS Treatment into Phase 3 Trials
PremiumCompany Announcements
InnoCare Advances MS Treatment into Phase 3 Trials
3M ago
9969
InnoCare Pharma Announces Strong Mid-Year Growth
PremiumCompany Announcements
InnoCare Pharma Announces Strong Mid-Year Growth
3M ago
9969
InnoCare Pharma Sets Date for Financial Update
PremiumCompany Announcements
InnoCare Pharma Sets Date for Financial Update
4M ago
9969
InnoCare Pharma Awards Employees with Share Scheme
PremiumCompany Announcements
InnoCare Pharma Awards Employees with Share Scheme
5M ago
9969
See More HK:9969 News >

Options Prices

Currently, No data available
---

Ownership Overview

1.66%96.63%
―
Insiders
1.66% Mutual Funds
― Other Institutional Investors
96.63% Public Companies and
Individual Investors
Detailed Ownership Overview >

9969 FAQ

What was InnoCare Pharma Ltd.’s price range in the past 12 months?
InnoCare Pharma Ltd. lowest stock price was HK$4.03 and its highest was HK$7.92 in the past 12 months.
    What is InnoCare Pharma Ltd.’s market cap?
    Currently, no data Available
    When is InnoCare Pharma Ltd.’s upcoming earnings report date?
    InnoCare Pharma Ltd.’s upcoming earnings report date is Mar 20, 2025 which is in 117 days.
      How were InnoCare Pharma Ltd.’s earnings last quarter?
      InnoCare Pharma Ltd. released its earnings results on Nov 11, 2024. The company reported -HK$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.011.
        Is InnoCare Pharma Ltd. overvalued?
        According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does InnoCare Pharma Ltd. pay dividends?
          InnoCare Pharma Ltd. does not currently pay dividends.
          What is InnoCare Pharma Ltd.’s EPS estimate?
          InnoCare Pharma Ltd.’s EPS estimate is -HK$0.09.
            How many shares outstanding does InnoCare Pharma Ltd. have?
            InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding.
              What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
              InnoCare Pharma Ltd. reported an EPS of -HK$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.259%.
                Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
                Currently, no hedge funds are holding shares in HK:9969
                ---

                InnoCare Pharma Ltd. Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Analyst Consensus

                Moderate Buy
                Average Price Target:
                HK$8.80 (42.86% Upside)

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                -12.74%
                12-Months-Change

                Fundamentals

                Return on Equity
                -5.28%
                Trailing 12-Months
                Asset Growth
                -2.74%
                Trailing 12-Months
                Top Smart Score Stocks >

                Company Description

                InnoCare Pharma Ltd.

                InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. Its commercial drug candidate is Orelabrutinib and clinical-stage drug candidates are ICP-192, ICP-105, ICP-723, and others.
                ---

                9969 Stock 12 Month Forecast

                Average Price Target

                HK$8.80
                ▲(42.86% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"HK$4","9":"HK$9","5.25":"HK$5.25","6.5":"HK$6.5","7.75":"HK$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$8.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,5.25,6.5,7.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.58,6.750769230769231,6.921538461538462,7.092307692307693,7.263076923076923,7.433846153846154,7.604615384615385,7.775384615384616,7.946153846153846,8.116923076923078,8.287692307692309,8.458461538461538,8.62923076923077,{"y":8.8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.58,6.750769230769231,6.921538461538462,7.092307692307693,7.263076923076923,7.433846153846154,7.604615384615385,7.775384615384616,7.946153846153846,8.116923076923078,8.287692307692309,8.458461538461538,8.62923076923077,{"y":8.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.58,6.750769230769231,6.921538461538462,7.092307692307693,7.263076923076923,7.433846153846154,7.604615384615385,7.775384615384616,7.946153846153846,8.116923076923078,8.287692307692309,8.458461538461538,8.62923076923077,{"y":8.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.13,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.06,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.11,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.64,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.95,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.3,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.02,"date":1700179200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.09,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Detailed Analyst Forecast >

                Technical Analysis

                Overall Consensus
                Neutral
                9Bullish
                3Neutral
                10Bearish
                Bullish
                Neutral
                Bearish
                Overall Consensus
                9
                3
                10
                Technical Analysis
                5
                3
                2
                Moving Averages
                4
                0
                8
                Technical Analysis >
                Similar Stocks
                Company
                Price & Change
                Follow
                9995
                RemeGen Co. Ltd. Class H
                ―
                ―
                9926
                Akeso, Inc.
                ―
                ―
                1699
                China Putian Food Holding Ltd.
                ―
                ―
                2222
                NVC International Holdings Ltd.
                ―
                ―
                Compare HK:9969 Stocks >

                Best Analysts Covering 9969

                1 Year
                Chris LuiJefferies
                1 Year Success Rate
                1/3 ratings generated profit
                33%
                1 Year Average Return
                -6.67%
                reiterated a buy rating 30 days ago
                Copying Chris Lui's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -6.67% per trade.
                Best Analyst Covering >
                Popular Stocks
                ---

                Become an Expert with TipRanks Premium

                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis
                Subscribe NowSee Plans & Pricing